Novo Nordisk A/S (NYSE:NVO) Holdings Reduced by Verus Capital Partners LLC

Verus Capital Partners LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 39.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,964 shares of the company’s stock after selling 2,545 shares during the period. Verus Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $341,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Natixis Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after acquiring an additional 30,420 shares in the last quarter. Versant Capital Management Inc bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $86,000. Finally, Talbot Financial LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $4,066,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.6 %

Shares of NYSE:NVO opened at $90.68 on Friday. The stock has a market capitalization of $406.91 billion, a price-to-earnings ratio of 27.56, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 1-year low of $77.82 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a 50 day moving average price of $84.82 and a 200 day moving average price of $106.72.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Analysts Set New Price Targets

NVO has been the subject of several recent analyst reports. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.